"EU"

The Phase I/Ib clinical trial of Mupadolimab, a humanized monoclonal antibody against CD73 and its combination with pablizumab, has received clinical trial approval from the NMPA Pharmacovigilance Center for use in patients with advanced solid tumors.

The results of a new study recently showed that Olutasidenib monotherapy in patients with relapsed/refractory acute myeloid leukaemia carrying the IDH1 mutation elicited high rates of complete remission with manageable toxicity.

Leukaemia is a very complex disease that causes fever and infection and bleeding, so it needs to be treated early so that it can be gradually controlled and the patient's symptoms can be gradually relieved

Recently, the frontier drug INT230-6 showed good tumour killing effects in the treatment of soft tissue sarcoma in the single arm phase 1/2 open-label clinical trial IT-01 (NCT03058289), and the drug showed good responses whether injected inside the tumour alone or in combination with the CTLA-4 immune checkpoint inhibitor ipilimumab.

Prior to the granting of marketing authorisation by the MHRA, Biyze® had been approved by the European Commission for a number of indications and is currently the only drug approved for the treatment of MZL in Great Britain.

Everyone wants to be in good health because we all know that good health is the only way to live a better life. However, many diseases still occur frequently nowadays, so we need to know about the common diseases

The US FDA has approved a new leukaemia drug, Olutasidenib, which has been shown to be effective and has a controlled safety profile, resulting in the complete disappearance of cancer cells in 35% of patients enrolled, with efficacy lasting up to 25.9 months.

The International Institute of Neuroscience (INI) in Hannover, Germany, is a hospital building shaped like a giant brain, with its main internal pillar being a lift that looks like a human brain stem, designed and built by Siemens in Germany.

Alveolar rhabdomyosarcoma is a rare but very deadly childhood tumour, and for more than 40 years there have been no new advances in the treatment of this disease. Recently, a study led by Professor Anton Henssen of the Charité University of Berlin has identified a promising new treatment for the disease.

The European Union has recently approved Roctavian, the first gene therapy for haemophilia A. The therapy has led to a significant reduction in the average number of annual bleeds and the average number of annual clotting factor VIII transfusions in patients with this severe bleeding disorder, and has a good safety profile.